These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27785928)

  • 1. Lomitapide for the treatment of hypertriglyceridemia.
    Brahm AJ; Hegele RA
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1457-1463. PubMed ID: 27785928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide.
    Sacks FM; Stanesa M; Hegele RA
    JAMA Intern Med; 2014 Mar; 174(3):443-7. PubMed ID: 24366202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lomitapide.
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):347-52. PubMed ID: 21846156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Lomitapide in Hypercholesterolemia.
    Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
    Rizzo M
    IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
    Davis KA; Miyares MA
    Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide.
    Giammanco A; Cefalù AB; Noto D; Averna MR
    Curr Med Chem; 2020; 27(23):3773-3783. PubMed ID: 30663562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide for the treatment of hypercholesterolemia.
    Berberich AJ; Hegele RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.
    Blom DJ; Fayad ZA; Kastelein JJ; Larrey D; Makris L; Schwamlein C; Bloeden L; Underberg J;
    J Clin Lipidol; 2016; 10(2):273-82. PubMed ID: 27055957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child.
    Chacra APM; Ferrari MC; Rocha VZ; Santos RD
    J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia.
    Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M
    J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.
    Neef D; Berthold HK; Gouni-Berthold I
    Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome.
    Cefalù AB; Giammanco A; Noto D; Spina R; Cabibi D; Barbagallo CM; Averna M
    Endocrine; 2021 Feb; 71(2):344-350. PubMed ID: 33006726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
    Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.